Latest News - Dementia & Cognitive Disorders

Wednesday, July 18, 2018

Investigational Tau Modifier Receives Orphan Drug Status for Progressive Supranuclear Palsy

The Food and Drug Administration (FDA) has granted an orphan drug designation to ASN120290 (Asceneuron SA, Lausanne, Switzerland) for the treatment of progressive supranuclear palsy (PSP). In preclini…

Read the full story

Monday, July 16, 2018

Phase 2 Confirmatory Trial of Bryostatin-1 for Alzheimer’s Disease Enrolls First Patient

The first individual has been enrolled into a confirmatory phase 2 clinical trial of bryostatin-1 (Neurotrope, New York, NY) for the treatment of persons with Alzheimer’s disease (AD). Subjects …

Read the full story

Friday, July 13, 2018

IncobotulinumtoxinA Approved for Treatment of Excessive Drooling

The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for incobotulinumtoxin A (Xeomin; Merz, Raleigh, NC) for the treatment of chronic sialorrhea, …

Read the full story

Tuesday, July 10, 2018

Can Patients Unique Brain Imaging Fingerprints Direct Clinical Management?

Researchers for the Alzheimer's Disease Neuroimaging Initiative from the Montreal Neurology Institute and Hospital (Montreal, Canada) have published results in the journal Neuroimaging, regarding …

Read the full story

Thursday, July 05, 2018

Positive Results for Potential Alzheimer’s Disease Treatment in Phase 2 Trial

In the first late-stage study to demonstrate potential disease modifying effects for the treatment of persons with Alzheimer’s disease, a monoclonal antibody to amyloid-ß protofibrils (BAN…

Read the full story

Thursday, June 14, 2018

Eisai Inc Launching Center for Genetics-Guided Dementia Discovery Center

Eisai Inc (Woodcliff Lake, NJ), the U.S. pharmaceutical subsidiary of Eisai Co, Ltd, has announced that the company is committing over $100 million as an initial investment to fund the Eisai Center fo…

Read the full story

Tuesday, June 12, 2018

Clinical Trials for Lanabecestat for Treatment of Alzheimer’s Disease Discontinued

Phase 3 clinical trials for lanabecestat (Lilly, Indianapolis, IN and AstraZeneca, Wilmington, DE) for the treatment of patients with Alzheimer’s disease (AD) are being discontinued. An independ…

Read the full story

Tuesday, June 05, 2018

American Academy of Sleep Medicine Issues Advisory: Insufficient Sleep May Increase Risk for Alzheimer’s Disease

The American Academy of Sleep Medicine (AASM) has issued a health advisory warning that insufficient or poor sleep may increase the risk of developing Alzheimer’s disease (AD). The AASM believes…

Read the full story

Friday, June 01, 2018

BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th

Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regarding new “right-to-…

Read the full story

Wednesday, May 30, 2018

Positive Effect of Exercise on Processing Speed, Executive Function, and Global Cognition Scores Confirmed

A meta-analysis from investigators Joyce Gomes-Osman, Danylo F. Cabral, Timothy P. Morris, and others was published in the journal Neurology Clinical Practice (published online May 30), and found good…

Read the full story

Wednesday, May 30, 2018

New Picture-Based Screening Tool for Dementia

News of the first picture-based screening tool for cognitive impairment was published in the Journal of the American Geriatrics Society (J Am Geriatr Soc. 2018:published online May 30). The new tool, …

Read the full story

Tuesday, May 22, 2018

New Potential Model to Estimate Lifetime Risk of Alzheimer's Dementia Using Biomarkers For Preclinical Disease

According to an article published to in the journal Alzheimer’s and Dementia (Alzheim and Dement. 2018:published online May 22). Researchers from the Department of Biostatistics at University of…

Read the full story

Wednesday, May 09, 2018

Depression in Older Adults May Be Linked to Memory Loss

In a study published in the journal  Neurology, researchers Zeki Al Hazzour, Michelle R. Caunca, Juan Carlos Nobrega, and others showed that depression in older adults correlates to worse ba…

Read the full story

Monday, April 16, 2018

New Data on Crenezumab and Gantenerumab

At the upcoming American Academy of Neurology (AAN) meeting beginning on April 21st, 2018, new data on investigational monoclonal antibodies against amyloid-ß (Aß) crenezumab and ganteneru…

Read the full story

Friday, April 13, 2018

Sleep Deprivation Increase Levels of Amyloid Beta in the Brain

Results published in the Proceedings of the National Academy of Sciences (PNAS:published online April 9, 2018) suggest that missing even 1 night of sleep can affect levels of Amyloid-ß (Aß…

Read the full story
Load More